BioMedNewsBreaks

ThursdayOct 01, 2020 12:22 pm

BioMedNewsBreaks – MediXall Group Inc. (MDXL) Launches New Telehealth Solutions for Uninsured, Underinsured

MediXall Group (OTCQB: MDXL), a technology and innovation-driven organization focused on reducing costs of health care and transforming the patient-provider experience through the launch of its Health Karma(TM) platform, today announced new virtual-care solutions for the uninsured and underinsured. Effective immediately, Americans can conduct an online medical visit with a board-certified medical professional to get fast and easy treatment, prescriptions and lab tests for routine medical issues. This new service is a result of Health Karma’s recent partnership with leading telehealth company MeMD. “Telehealth will continue to be a popular option for patients, providers and employers beyond the pandemic,” Health…

Continue Reading

ThursdayOct 01, 2020 10:38 am

BioMedNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Achieves Critical Milestone for Production of Lead Drug Candidate

CNS Pharmaceuticals (NASDAQ: CNSP), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers of the brain and central nervous system, today announced that its GMP manufacturer partner NCK A/S, received a Certificate of Analysis (“CoA”) for its Active Pharma Ingredient (“API”), clearing it for use in the production of Berubicin. CNS Pharmaceuticals previously announced entry into a contract with NCK A/S, a GMP manufacturer of complex drugs and the previous producer of Berubicin for Reata Pharmaceuticals, for the large-scale production of Berubicin, CNSP’s lead drug candidate for the treatment of glioma brain tumors. "We…

Continue Reading

ThursdayOct 01, 2020 9:55 am

BioMedNewsBreaks – VistaGen Therapeutics (NASDAQ: VTGN) CEO Discusses ‘Sea of Change’ to Future of Anxiety Treatment

VistaGen Therapeutics’ (NASDAQ: VTGN) CEO Shawn Singh authored a recent article for Life Science Leader titled, “The Future of Anxiety Treatment Will Be Drastically Different.” In the piece, Singh, an experienced professional who has dedicated over 25 years to biopharma and medical device industries, addresses the current standard of care for anxiety disorders and its inability to meet the growing need. “As researchers learn more about psychological therapy for anxiety disorders and medication options to complement it, efforts are underway to develop innovative medications to displace current anti-anxiety drugs that are not effective for all patients and are associated with…

Continue Reading

WednesdaySep 30, 2020 9:35 am

BioMedNewsBreaks – VistaGen Therapeutics (NASDAQ: VTGN) CEO Addresses ‘Multi-Pronged Approach’ to Growing Problem of Workplace Stress and Anxiety

VistaGen Therapeutics’ (NASDAQ: VTGN) CEO Shawn Singh authored a recent article for Business.com regarding the COVID-19 pandemic and resulting stress and anxiety impacts to the workplace. In the piece, Singh indicates that stress and anxiety, often driven by job-related issues, when left unchecked can rise to the level of an anxiety disorder with negative consequences for physical health, mental well-being, productivity and career opportunities. The global pandemic has exacerbated this largely unaddressed and widespread mental health problem in the workplace, markedly reflecting in increased prescriptions for antidepressant and anti-anxiety medications, many associated with significant side effects and safety concerns. “To…

Continue Reading

MondaySep 28, 2020 11:54 am

BioMedNewsBreaks – VistaGen Therapeutics (NASDAQ: VTGN) Featured in Equity Research Company Update

VistaGen Therapeutics (NASDAQ: VTGN), a biopharmaceutical company developing new generation medicines for anxiety, depression and other central nervous system (“CNS”) disorders, was featured in an Equity Research Company Update by Maxim Group LLC. The report, titled “Benzo-Benefits Without the Benzo-Baggage – The Case for PH94B Builds,” highlights potential benefits of VistaGen’s PH94B drug candidate, a nasal spray designed for treatment of adults with social anxiety disorder, as compared to treatment with benzodiazepines. The report reads, “Benzodiazepines (benzos) have been available to treat anxiety since the 1960s, and include well-known products such as Xanax, Ativan, and Klonopin. These drug compounds work…

Continue Reading

FridaySep 25, 2020 2:45 pm

BioMedNewsBreaks – 180 Life Sciences Corp. Advancing Lead Program, Plans Additional Clinical Trials

180 Life Sciences, a clinical-stage biotechnology company, is dedicated to producing solutions designed to battle inflammation when the body’s natural processes go awry. The company’s primary focus is to treat fibrosis and inflammation using anti-TNF therapy, designed to block the activity of TNF, a substance in the body that can cause inflammation and lead to immune-system diseases. The company is advancing on this front as discussed by a recent article that reads, “180 Life Sciences’ lead program is in phase 2b/3 clinical trials and expects to deliver its first results next year. Other clinical trials planned by the company are…

Continue Reading

ThursdaySep 24, 2020 12:58 pm

BioMedNewsBreaks – Humanigen Inc. (NASDAQ: HGEN) Secures $78.2M in Underwritten Public Offering

Humanigen (NASDAQ: HGEN), a clinical-stage biopharmaceutical company focused on preventing and treating an immune hyper-response called “cytokine storm” with its lead drug candidate lenzilumab, has closed an underwritten public offering of 9,200,000 shares of common stock, including 1,200,000 shares pursuant to the full exercise of the over-allotment option granted to the underwriters. According to the update, Humanigen secured approximately $78.2 million in gross proceeds, with each of the shares sold at the public offering price of $8.50. The company intends to use the proceeds to support its manufacturing, production and commercial preparation activities relating to lenzilumab as a potential therapy…

Continue Reading

ThursdaySep 24, 2020 11:04 am

BioMedNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Partners with Leading Medical Imaging Group for Upcoming Berubicin Clinical Trials

CNS Pharmaceuticals (NASDAQ: CNSP), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers of the central nervous system, has announced that it will partner with Image Analysis Group (“IAG”) for planned Berubicin clinical trials. IAG, a leading medical imaging group, and CNS will work together to provide critical imaging services and imaging data analysis for the trials. IAG has an extensive background of partnering with oncology companies to deliver centralized readings and analysis of patient responses in real time. IAG’s expertise will allow CNS to review efficacy assessments and explore the advanced-treatment manifestations. Because…

Continue Reading

WednesdaySep 23, 2020 9:45 am

BioMedNewsBreaks – Predictive Oncology (NASDAQ: POAI) Granted License for Additional 71 Unique Ovarian Cancer Cell Lines

Predictive Oncology (NASDAQ: POAI), a knowledge-driven company focused on applying artificial intelligence (“AI”) to personalized medicine and drug discovery, has announced that TumorGenesis, a division of the company, has received a license for an additional 71 unique ovarian cancer call lines. The licensing comes from England-based Ximbio, the largest nonprofit in the world dedicated to life science reagents. TumorGenesis now has a total of 96 unique patient-derived ovarian cancer cell lines. Research such as that conducted by TumorGenesis is  the foundation of preclinical research and development. “It is remarkable that the UK cancer researchers using the same media mixes now…

Continue Reading

TuesdaySep 22, 2020 5:03 pm

BioMedNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP), Sub-Licensee Partner Advancing Lead Drug Candidate in First-Ever Phase 1 and Phase 2 Clinical Trials

CNS Pharmaceuticals (NASDAQ: CNSP), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers of the brain and central nervous system, is advancing its leading drug candidate, Berubicin, to move forward with clinical trials in Poland. This move comes after sub-licensee WPD Pharmaceuticals Inc. has identified a contract research organization — Worldwide Clinical Trials — to coordinate and supervise Phase 1 and Phase 2 trials in the European country (http://ibn.fm/iFYph). A recent article discussing this reads, “Berubicin is proposed for the treatment of glioblastoma multiforme (‘GBM’), an aggressive and incurable form of brain cancer. Berubicin also…

Continue Reading